2015
DOI: 10.1007/s40265-015-0408-8
|View full text |Cite
|
Sign up to set email alerts
|

Liraglutide: A Review of Its Use in the Management of Obesity

Abstract: Globally, obesity has reached epidemic proportions and poses an ever increasing burden from a societal and healthpayer perspective. Although lifestyle interventions are fundamental in its management, in the real world setting most obese or overweight adults require adjunctive pharmacotherapy to achieve clinically relevant reductions in bodyweight (i.e. a ≥5 % reduction). Subcutaneous liraglutide (Saxenda(®)) 3 mg once daily is indicated as an adjunct to a reduced-calorie diet and increased physical activity fo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
20
0
2

Year Published

2016
2016
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 34 publications
(22 citation statements)
references
References 34 publications
0
20
0
2
Order By: Relevance
“… 25 26 A possible explanation for the relation between higher baseline proinsulin and potential greater HbA1c reduction is that GLP-1 RA influences insulin resistance by decreasing visceral abdominal fat. 22 Moreover, it is also possible that the association between proinsulin and HbA1c reduction could be explained by GLP-1 RA working by increasing the processing of proinsulin to insulin in beta cells, something that has been shown in mice. 27 If this is the case, it could be imagined that those with a higher proinsulin level, and thus a higher insulin resistance and beta cell dysfunction, would have the most effect from GLP-1 RA treatment.…”
Section: Discussionmentioning
confidence: 99%
“… 25 26 A possible explanation for the relation between higher baseline proinsulin and potential greater HbA1c reduction is that GLP-1 RA influences insulin resistance by decreasing visceral abdominal fat. 22 Moreover, it is also possible that the association between proinsulin and HbA1c reduction could be explained by GLP-1 RA working by increasing the processing of proinsulin to insulin in beta cells, something that has been shown in mice. 27 If this is the case, it could be imagined that those with a higher proinsulin level, and thus a higher insulin resistance and beta cell dysfunction, would have the most effect from GLP-1 RA treatment.…”
Section: Discussionmentioning
confidence: 99%
“…Several lines of clinical evidence implicate a role for altered GLP-1 function in the pathophysiology of human obesity and a number of recent clinical trials have validated the clinical efficacy of long-term once daily SC 3 mg liraglutide (Saxenda) as an adjunct to calorie-restriction and exercise counselling in obese and overweight individuals with at least one weight related comorbidity. Significant improvements in clinical outcome measures such as body weight, anthropometric and cardiometabolic parameters, and indices of glucose tolerance have been observed and recently reviewed elsewhere[204]. Though March 2015 saw the EMA grant marketing authorization for 3 mg liraglutide as a weight-management agent in all 28 EU states[45], cost-benefit of funding treatment on the NHS undoubtedly contributes to the uncertainty of launch plans in the United Kingdom at present[46].…”
Section: A Role For Glp-1 In the Pharmacotherapy Of Clinical Obesitymentioning
confidence: 99%
“…Native GLP-1 is rapidly degraded by endogenous DPP-4 enzyme promoting a short half-life of 1.5 -2 minutes. Liraglutide is stable against DPP-4 degradation and has a prolonged plasma half-life of 13 hours [15] [16]. Similar to endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor.…”
Section: Pharmacologymentioning
confidence: 99%